Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Bevacizumab and Lomustine in Treating Patients With Glioblastoma Multiforme in First Recurrence
This study is not yet open for participant recruitment.
Verified September 2011
by National Cancer Institute (NCI)
Study NCT01290939 Information provided by National Cancer Institute (NCI)
First Received on February 4, 2011. Last Updated on September 15, 2011
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Cognitive/Functional Effects
Additional conditions recognized in this trial
Central Nervous System Neoplasms
Glioblastoma
Nervous System Neoplasms
Recurrence
More general conditions related to this trial
Astrocytoma
Disease Attributes
Glioma
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neoplasms, Neuroepithelial
Nervous System Diseases
Neuroectodermal Tumors
Pathologic Processes
Interventions listed in this trial
bevacizumab
lomustine
DNA methylation analysis
laboratory biomarker analysis
cognitive assessment
quality-of-life assessment
More general drug interventions related to this trial
Alkylating Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Growth Inhibitors
Growth Substances
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
European Organisation for Research and Treatment of Cancer - EORTC
Back to top of Main Content
